NanoViricides Sets 2025 Shareholder Meeting Amid Broad Antiviral Drug Development

NanoViricides, Inc. announced that its Annual Shareholders Meeting will be held at 10 a.m. on Saturday, November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The clinical-stage company, trading on NYSE American under symbol NNVC, is developing broad-spectrum antiviral drugs designed to prevent viral escape, positioning itself at the forefront of antiviral therapeutics development.

The company's lead drug candidate, NV-387, represents a significant advancement in antiviral treatment with planned development for respiratory syncytial virus, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX and smallpox infections. This broad-spectrum approach could potentially address multiple viral threats with a single therapeutic platform, reducing the need for virus-specific treatments. The company's other advanced candidate, NV-HHV-1, targets shingles treatment, addressing a persistent viral infection affecting millions worldwide.

NanoViricides operates on a unique business model, licensing technology from TheraCour Pharma, Inc. for specific antiviral applications. The company holds exclusive, sub-licensable field licenses for drugs developed in several licensed fields from TheraCour, as detailed in their corporate information available at https://www.nanoviricides.com. This strategic partnership provides NanoViricides with access to proprietary nanomedicine technology that forms the foundation of their drug development programs.

The company's platform technology encompasses development against numerous viral diseases including oral and genital herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, rabies, dengue fever, and Ebola virus. Their perpetual license covers specific targeting mechanisms for multiple significant human viral diseases, demonstrating the breadth of their technological approach. The company intends to pursue additional licenses for RSV, poxviruses, and enteroviruses pending successful initial research outcomes.

Currently, NanoViricides is focused on advancing NV-387 into Phase II human clinical trials, though the company notes it cannot project exact dates for filing Investigational New Drug applications due to dependence on external collaborators and consultants. This transparency about development timelines provides important context for investors and stakeholders following the company's progress. Additional company updates and information are available through their newsroom at https://ibn.fm/NNVC.

The development of effective broad-spectrum antiviral treatments carries substantial implications for global public health. Current antiviral therapies often target specific viruses, requiring distinct treatments for different infections. NanoViricides' platform approach could potentially streamline treatment protocols and provide rapid response capabilities for emerging viral threats. The company's technology, based on special purpose nanomaterials for antiviral therapy, represents an innovative approach to combating viral diseases that have historically challenged medical science.

As with all pharmaceutical development, the path forward involves significant challenges and requires substantial capital investment. The company appropriately notes that there can be no assurance that their candidates will show sufficient effectiveness and safety for human clinical development or that successful laboratory results will translate to successful clinical trials or marketable products. This candid assessment underscores the high-risk, high-reward nature of antiviral drug development while highlighting the substantial potential benefits if successful.